

<input type="checkbox"/> New to Therapy
<input type="checkbox"/> Current Therapy

Patient Information	Prescriber Information
---------------------	------------------------

Patient Name: _____ Date of Birth: _____ Gender: _____ SS#: _____ Address: _____ City: _____ State: _____ Zip: _____ Home Phone: _____ Work Phone: _____ Cell Phone: _____ E-mail: _____ Please attach copy of front and back of patient's prescription ins. card(s) if applicable Insurance Company Name: _____ Insurance Company Phone: _____ Policy holder: _____ Policy holder Employer: _____ Relationship to Patient: _____ ID#: _____ Group#: _____ RxBIN: _____ RxPCN: _____	Practice/ Organization Name: _____ Physician Name: _____ Contact Person: _____ Contact's Phone: _____ Address: _____ City: _____ State: _____ Zip: _____ Office Phone#: _____ Office Fax#: _____ DEA# _____ NPI# _____ License#: _____ Medicaid UPIN#: _____ Physician Specialty: _____ Date Shipment Needed: _____ Ship to: <input type="checkbox"/> Patient <input type="checkbox"/> Prescriber <input type="checkbox"/> Other _____ Shipment Address: _____ Attn: _____ City: _____ State: _____ Zip: _____ <i>If shipped to the physician's office, physician accepts on behalf of patient for administration in office.</i>
--	--

Clinical Information

Diagnosis: <input type="checkbox"/> K51.____ Other: _____ ICD 10 Code: _____ Patients Allergies: _____ Date of Diagnosis or Years with Disease: _____ Latex allergy: <input type="checkbox"/> NO <input type="checkbox"/> YES Patient Weight: _____ <input type="checkbox"/> kg or <input type="checkbox"/> lbs Patient Height: _____ <input type="checkbox"/> in <input type="checkbox"/> cm Hepatitis Status: _____ Has the patient had a NEGATIVE tuberculin skin test? <input type="checkbox"/> YES <input type="checkbox"/> No Date: ____/____/_____ Prior Medications and length of treatment: _____ Is patient on samples? <input type="checkbox"/> Yes <input type="checkbox"/> No Expected First Dose Date: _____ Injection Instruction needed: <input type="checkbox"/> Yes <input type="checkbox"/> No Specialty Pharmacy to coordinate home health infusion nurse visit as necessary? <input type="checkbox"/> Yes <input type="checkbox"/> No <p align="center">If ancillary supplies needed (i.e. Diluents, Flushes, EpiPen, etc) Please send additional prescriptions as needed.</p>

Privacy & Confidentiality of Information Notice: This communication may contain non-public, confidential, or legally privileged information intended for the sole use of the designated recipient(s). If you are not the intended recipient, or have received this communication in error, please notify the sender immediately by reply email or by telephone at the number stated above and delete all copies of this communication, including any attachments, without reading them or saving them to disk. If you are the intended recipient, you must secure the contents of this communication in accordance with all applicable state or federal requirements related to the privacy and confidentiality of information, including the HIPAA Privacy guidelines.

Patient Name: _____ Patient Date of Birth: _____
 Prescriber Name: _____ Office Phone: _____ Date: _____
 Prescriber Address: _____

Medication	Strength	Dose and Directions	Quantity/Refills
<input type="checkbox"/> Entyvio® (vedolizumab)	<input type="checkbox"/> 300mg Vial <input type="checkbox"/> 108mg/0.68mL Pen <input type="checkbox"/> 108mg/0.68mL PFS	<input type="checkbox"/> Initial Dose: 300mg IV @ weeks 0, 2, and 6 <input type="checkbox"/> Initial Dose: 300mg IV @ week 0 and 2 <input type="checkbox"/> Maintenance Dose: 108mg SC at week 6, then every 2 weeks thereafter <input type="checkbox"/> Maintenance Dose: 300mg IV every 8 weeks	Quantity: _____ Refills: _____
<input type="checkbox"/> Humira® (adalimumab)	<input type="checkbox"/> 20mg/0.2mL CF PFS <input type="checkbox"/> 40mg/0.4mL CF Pen <input type="checkbox"/> 40mg/0.4mL CF PFS <input type="checkbox"/> 40mg/0.8mL Pen <input type="checkbox"/> 40mg/0.8mL PFS <input type="checkbox"/> 80mg/0.8mL CF Pen	<input type="checkbox"/> Starter Kit: 160 mg SC on day 1, 80 mg on day 15, then 40mg every other week <input type="checkbox"/> Pediatric Starter Kit (>40kg): 160mg SC on day 1, 80mg on days 8 and 15, then continue as instructed. <input type="checkbox"/> Pediatric Starter Kit (<40kg): 80mg SC on day 1, 40mg on days 8 and 15, then continue as instructed <input type="checkbox"/> Starter Kit: Other: _____ <input type="checkbox"/> Maintenance Dose: 40mg SC every other week <input type="checkbox"/> Maintenance Dose: 40mg SC every week <input type="checkbox"/> Maintenance Dose: 80mg SC every other week <input type="checkbox"/> Maintenance Dose: 20mg SC every week <input type="checkbox"/> Maintenance Dose: Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Remicade® (infliximab) <input type="checkbox"/> Avsola® <input type="checkbox"/> Inflectra® <input type="checkbox"/> Infliximab® <input type="checkbox"/> Renflexis®	<input type="checkbox"/> 100mg/mL Vial	Initial Dose: <input type="checkbox"/> 5mg/kg @ 0, 2, 6 weeks Maintenance Dose: <input type="checkbox"/> 5mg/kg every 8 weeks <input type="checkbox"/> 10mg/kg every 8 weeks <input type="checkbox"/> Other dosing: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Rinvoq® (upadacitinib)	Initial: <input type="checkbox"/> 45mg Maintenance: <input type="checkbox"/> 30mg <input type="checkbox"/> 15mg	<input type="checkbox"/> Initial Dose: 45mg PO once daily for 8 weeks <input type="checkbox"/> Maintenance Dose: 1 tablet by mouth once daily Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Other:	<input type="checkbox"/> Strength:	<input type="checkbox"/> Dose:	Quantity: _____ Refills: _____

Prescriber Signature: X _____

If Brand required "Dispense as Written" must be handwritten.

Privacy & Confidentiality of Information Notice: This communication may contain non-public, confidential, or legally privileged information intended for the sole use of the designated recipient(s). If you are not the intended recipient, or have received this communication in error, please notify the sender immediately by reply email or by telephone at the number stated above and delete all copies of this communication, including any attachments, without reading them or saving them to disk. If you are the intended recipient, you must secure the contents of this communication in accordance with all applicable state or federal requirements related to the privacy and confidentiality of information, including the HIPAA Privacy guidelines.

Patient Name: _____ Patient Date of Birth: _____
 Prescriber Name: _____ Office Phone: _____ Date: _____
 Prescriber Address: _____

Medication	Strength	Dose and Directions	Quantity/Refills
<input checked="" type="checkbox"/> Simponi® (golimumab)	<input type="checkbox"/> 100mg/mL PFS <input type="checkbox"/> 100mg/mL Prefilled SmartJect Pen	<input type="checkbox"/> Initial Dose: Inject 200mg SC at Week 0, followed by 100mg at Week 2, then every 4 weeks <input type="checkbox"/> Maintenance Dose: Inject 100mg SC every 4 weeks <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Stelara® (ustekinumab)	Initial: <input type="checkbox"/> 130mg/26mL Vial Maintenance: <input type="checkbox"/> 90mg/mL PFS	<input type="checkbox"/> Initial Single Dose IV x 1 hour: <input type="checkbox"/> <55g: 260mg <input type="checkbox"/> 56-85kg: 390mg <input type="checkbox"/> >85kg: 520mg <input type="checkbox"/> Maintenance Dose: 90mg subcutaneously every 8 weeks <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Xeljanz® (tofacitinib)	Initial: <input type="checkbox"/> 10mg Maintenance: <input type="checkbox"/> 10mg <input type="checkbox"/> 5mg	<input type="checkbox"/> Initial dose: 10mg PO twice daily for at least 8 weeks <input type="checkbox"/> Maintenance: Take 1 tablet by mouth twice daily <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Xeljanz XR® (tofacitinib)	Initial: <input type="checkbox"/> 22mg Maintenance: <input type="checkbox"/> 22mg <input type="checkbox"/> 11mg	<input type="checkbox"/> Initial dose: 22mg PO once daily for at least 8 weeks <input type="checkbox"/> Maintenance: Take 1 tablet by mouth once daily <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Other:	<input type="checkbox"/> Strength:	<input type="checkbox"/> Dose:	Quantity: _____ Refills: _____

Prescriber Signature: X _____

If Brand required "Dispense as Written" must be handwritten.

Privacy & Confidentiality of Information Notice: This communication may contain non-public, confidential, or legally privileged information intended for the sole use of the designated recipient(s). If you are not the intended recipient, or have received this communication in error, please notify the sender immediately by reply email or by telephone at the number stated above and delete all copies of this communication, including any attachments, without reading them or saving them to disk. If you are the intended recipient, you must secure the contents of this communication in accordance with all applicable state or federal requirements related to the privacy and confidentiality of information, including the HIPAA Privacy guidelines.